The US Food and Drug Administration (FDA) has granted approval to Regeneron Pharmaceuticals’ fully human monoclonal antibody ...

Libtayo gained FDA approval as the first immunotherapy for high-risk cutaneous squamous cell carcinoma, promising improved ...

The FDA has handed out the first nine national priority vouchers, positioning companies including Merck KGaA, Regeneron and Sanofi to complete the approval process in one to two months.

Regeneron Pharmaceuticals recently received U.S. FDA approval and a positive opinion from the European Medicines Agency's ...

FDA approves Regeneron's Libtayo for adults with high-risk cutaneous squamous cell carcinoma after surgery and radiation, ...

Regeneron Pharmaceuticals, Inc. REGN announced that the FDA has approved the label expansion of PD-1 inhibitor Libtayo ...

The U.S. Food and Drug Administration on Wednesday approved Regeneron Pharmaceuticals' triple antibody cocktail as the first Ebola virus treatment, lending validation to similar drugs being developed ...

The U.S. Food and Drug Administration on Wednesday cleared Regeneron Pharmaceuticals’ immunotherapy, Libtayo, as an add-on ...

Libtayo’s latest approval for a type of skin cancer should boost future sales, according to one analyst, but doesn’t have the ...

Retail chatter picked up around Regeneron Pharmaceuticals late Wednesday after the U.S. Food and Drug Administration (FDA) ...

Regeneron Pharmaceuticals' Libtayo won approval to treat certain patients with cutaneous squamous cell carcinoma, a type of skin cancer, from the Food and Drug Administration. The pharmaceutical ...

Investing.com -- Regeneron Pharmaceuticals (NASDAQ:REGN) stock rose 2% Wednesday following the FDA’s approval of its drug Libtayo for the adjuvant treatment of adults with cutaneous squamous cell ...